Western Oncolytics Ltd. logo

Western Oncolytics Ltd.

Western Oncolytics is a biotech company developing novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells. Western Oncolytics licensed novel WO-12 cancer therapy from University of Pittsburgh developed by Prof. Stephen Thorne, that use genetically engineered viruses to attack only cancer cells of solid tumor types while also delivering therapeutic genes.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.westernoncolytics.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
265 William Pitt Way, PA 15238
Pittsburgh
United States
Email
Contact Number
+1 412-826-3020

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/western-oncolytics-ltd-” connections=”true” suffix=””]

In July 2016, Pfizer and Western Oncolytics signed a collaboration on preclinical and clinical development of WO-12 through Phase I trials. Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12. Financial terms of the agreement were not disclosed.

In June 2014, Western Oncolytics secured $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy.